Jiangsu Kanion Pharmaceutical Co.Ltd(600557)
2021 Corporate Social Responsibility Report
March 2022
catalogue
Declare that 3 interpretation 3 about this report 42021 annual honorary awards 5 I. Company Profile 7 II. Corporate governance 8 III. corporate culture construction 11 IV. environmental protection and sustainable development V. R & D innovation and drug quality 21 VI. shareholder returns and investor relations 24 VII. Employee rights and interests and development 26 VIII. Brand building 30 IX. party and League Construction 33 X. repay the society 37 Xi. Future outlook thirty-nine
statement
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this report, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
interpretation
Jiangsu Kanion Pharmaceutical Co.Ltd(600557) , the company and the company refer to Jiangsu Kanion Pharmaceutical Co.Ltd(600557)
GMP refers to the abbreviation of good manufacturing practice, which is the standard of drug production quality management.
Gap refers to the abbreviation of the production quality management specification of traditional Chinese medicine (for Trial Implementation)
Chinese herbal medicine gap.
About this report
This report is the 2021 corporate social responsibility report issued by Jiangsu Kanion Pharmaceutical Co.Ltd(600557) to the public. The period is from January 1, 2021 to December 31, 2021. It is disclosed simultaneously with Jiangsu Kanion Pharmaceutical Co.Ltd(600557) 2021 annual report.
This report aims to truly reflect the development and practice of the company’s social responsibility in 2021, and summarizes the company’s contributions to society, economy, environment and sustainable development in its business activities in 2021. Publicly report the company’s operation to shareholders, partners, government, employees and other stakeholders, and help stakeholders understand the company’s social responsibility practice.
During the preparation of the report, the company followed the self regulatory guidelines for listed companies of Shanghai Stock Exchange No. 1 – standardized operation published by Shanghai Stock Exchange, And earnestly implement the relevant requirements of Article 5 of the company law that “when engaging in business activities, the company must abide by laws, administrative regulations, social ethics and business ethics, be honest and trustworthy, accept the supervision of the government and the public, and bear social responsibility”.
This report was deliberated and adopted at the 14th meeting of the 7th board of directors held on March 2, 2022.
2021 annual honorary awards
National level: Kangyuan national postdoctoral workstation is evaluated as excellent and approved by the state as a workstation for independent recruitment of postdoctoral qualifications – Ministry of human resources and social security Chairman Xiao Wei of the National Postdoctoral Management Committee was elected academician of the Chinese Academy of Engineering – Chairman Xiao Wei of the Chinese Academy of engineering was selected as Qihuang scholar in 2021 – the State Administration of traditional Chinese medicine participated in the completion of the project of innovative research and development theory and key technologies of traditional Chinese medicine based on “substance, pharmacokinetics and efficacy” and their application, It also won the second prize of the national science and Technology Progress Award in 2020 – the innovative traditional Chinese medicine R & D team of Kangyuan Institute of modern traditional Chinese medicine of the State Council was rated as the “sixth national advanced collective of professional and technical talents” – the Jiangsu Kanion Pharmaceutical Co.Ltd(600557) technology center of the Ministry of human resources and social security was selected as the 20th National Youth Civilization – the Kangyuan Guizhi Fuling Capsule of the Central Committee of the Communist Youth League was awarded “2021 China Meheco Group Co.Ltd(600056) brand list” grassroots terminal Award – micnet Jiangsu Kanion Pharmaceutical Co.Ltd(600557) won the “best industrial enterprise of China Meheco Group Co.Ltd(600056) R & D product line in 2021″ – China Meheco Group Co.Ltd(600056) Industrial Information Center “2021 top 50 of Chinese traditional medicine R & D strength list”, Jiangsu Kanion Pharmaceutical Co.Ltd(600557) ranked first again in the traditional Chinese medicine industry – “2021 great health industry high quality development conference and the sixth China Meheco Group Co.Ltd(600056) R & D · Innovation Summit” Jiangsu Kanion Pharmaceutical Co.Ltd(600557) employee Zhang Wenyu was awarded the title of “great craftsman” of the national energy chemical geological system in 2021 – Provincial level of China energy chemical Geological union: Jiangsu Kanion Pharmaceutical Co.Ltd(600557) won the title of “2021 Jiangsu social responsibility enterprise” Honorary title – Xinhua newspaper media group Jiangsu Kanion Pharmaceutical Co.Ltd(600557) modern traditional Chinese medicine digital extraction and refining factory won the “pioneer of workers in Jiangsu Province” – Jiangsu Federation of trade unions Jiangsu Kanion Pharmaceutical Co.Ltd(600557) was rated as “excellent unit of quality management (QC) group activity in Jiangsu pharmaceutical industry in 2021” ——Researcher Xiao Wei of Jiangsu Pharmaceutical Quality Management Association won the first Jiangsu Provincial Science and technology innovation and Development Award. The Jiangsu Kanion Pharmaceutical Co.Ltd(600557) archives of Jiangsu Provincial People’s government was awarded the provincial “four-star archives” – Jiangsu Lianyungang Port Co.Ltd(601008) Municipal Archives Bureau
Awarded as a contract abiding and trustworthy enterprise in Jiangsu Province – Jiangsu Enterprise Credit Management Association municipal level: unit with remarkable achievements in talent introduction and material use – Jiangsu Lianyungang Port Co.Ltd(601008) municipal talent work leading group office Jiangsu Lianyungang Port Co.Ltd(601008) municipal key industrial chain “chain leader” ——Municipal Committee of the Communist Youth League — the Fourth Municipal Committee of the Communist Youth League
1、 Company profile
Jiangsu Kanion Pharmaceutical Co.Ltd(600557) formerly known as Jiangsu Lianyungang Port Co.Ltd(601008) traditional Chinese medicine factory established in 1975, it was restructured in 1996 and listed on the main board of Shanghai Stock Exchange in 2002. The industry of the company is pharmaceutical manufacturing, and its main business involves the R & D, production and sales of drugs. Adhering to the good vision of “modern traditional Chinese medicine, Kangyuan intelligent manufacturing”, the company adheres to innovation driven, and comprehensively promotes the coordinated development of traditional Chinese medicine and chemical medicine. The company is a national technological innovation demonstration enterprise, a national key high-tech enterprise, a national innovation pilot enterprise, a national intellectual property demonstration enterprise, and one of the top 100 enterprises in the national pharmaceutical industry. Over the years, the company has not only achieved good economic benefits and created profit returns for shareholders, but also actively assumed social responsibilities and achieved good social benefits.
The company’s main product line focuses on the areas of viral infection, gynecopathy, cardiovascular and cerebrovascular diseases, orthopedic diseases and other traditional Chinese medicine. The representative products of viral infectious disease product line include re Du Ning Injection, Jin Zhen oral liquid, Xingbei Zhike granule, etc. The representative varieties of gynecological product line include Guizhi Fuling Capsule, Sanjie analgesic capsule, etc; The representative varieties of cardio cerebrovascular product line include ginkgo diterpene lactone glucosamine injection, Tianshu capsule, Longxue Tongluo capsule, Yixinshu tablet, Dazhu Rhodiola capsule, Cistanche glycoside capsule, etc; The representative varieties of orthopedics and traumatology product line include Yaobitong capsule, Compound Nanxing Zhitong ointment, epimedium total flavonoids capsule, anti bone hyperplasia capsule, etc; At the same time, it also has special pediatric drugs such as Jiuwei Xifeng granule for the treatment of children’s multiple tic.
2021 is a year of great significance in the development of the company. Facing the surging market changes in the pharmaceutical industry, the company faced difficulties and challenges, continued to promote multi-dimensional innovation in sales, R & D, production and management, and made new achievements in the fierce market competition. In 2021, the company was selected as one of the top 100 excellent Chinese medicine enterprises (No. 8). The project of innovative research and development theory and key technology of traditional Chinese medicine and its application based on “substance – pharmacokinetics – efficacy” participated by the company won the second prize of national science and Technology Progress Award in 2020; In 2021, the top 50 of the 2021 ranking list of Chinese traditional medicine R & D strength was officially released. 50 enterprises led the innovation frontier of traditional Chinese medicine, Jiangsu Kanion Pharmaceutical Co.Ltd(600557) once again took the lead and won the crown. The comprehensive strength and brand influence were continuously enhanced. This year, researcher Xiao Wei, chairman of the company, was elected academician of the Chinese Academy of engineering; The innovative traditional Chinese medicine R & D team of Jiangsu Kangyuan modern traditional Chinese medicine research institute won the title of the sixth “national outstanding professional and technological advanced collective”, which is the only advanced collective in previous cities under the jurisdiction of Jiangsu Province. The State Food and Drug Administration announced and approved the application for listing registration of Jiangsu Kanion Pharmaceutical Co.Ltd(600557) Yinqiao Qingre tablet, which is the first class 1.1 new traditional Chinese medicine drug approved for listing since the implementation of the new registration classification of traditional Chinese medicine on July 1, 2020.
In 2022, Jiangsu Kanion Pharmaceutical Co.Ltd(600557) will strive to create a new situation of high-quality development, actively practice social responsibility, promote the coordinated and unified development of economic benefits, social benefits and environmental benefits, and combine corporate social responsibility with corporate competitiveness. It has become the mission of Kangyuan pharmaceutical in the new era! 2、 Corporate governance
During the reporting period, the company further improved the corporate governance structure, actively fulfilled the obligation of information disclosure and standardized the operation of the company in strict accordance with the requirements of laws, regulations and normative documents such as the company law, the securities law, the governance standards for listed companies and the Listing Rules of Shanghai Stock exchange.
The rights and responsibilities of the general meeting of shareholders, the board of directors, the board of supervisors and the management of the company are clear, and the actual situation of corporate governance basically meets the requirements of the normative documents on the governance of listed companies issued by the CSRC. The details are as follows: the company hired Lixin Certified Public Accountants (special general partnership) to issue the internal control audit report (Xin Hui Shi Bao Zi [2022] No. zh10006) on the company’s internal control self-evaluation report in 2021, It is considered that Jiangsu Kanion Pharmaceutical Co.Ltd(600557) has maintained effective internal control over financial reporting in all major aspects in accordance with the basic norms of enterprise internal control and relevant regulations on December 31, 2021. For details, see the relevant announcement disclosed by the company on the website of Shanghai Stock Exchange on the same day.
(I) controlling shareholders and the company
The company has independent business and independent operation ability, achieves “five independence” with the controlling shareholders in terms of personnel, assets, finance, organization and business, and the company’s board of directors, board of supervisors and internal institutions can operate independently. The company has established relevant provisions through the rules of procedure of the general meeting of shareholders, the articles of association, the decision-making system of connected transactions and the special system for preventing the occupation of funds by controlling shareholders and related parties, and established a long-term mechanism to prevent controlling shareholders and their affiliated enterprises from occupying the funds of listed companies and infringing on the interests of listed companies. The controlling shareholders strictly regulate their own behavior, the related party transactions with the company are fair and reasonable, and there has been no major shareholder occupying the funds and assets of the listed company.
(II) shareholders and general meeting of shareholders
The company convenes and convenes the general meeting of shareholders in strict accordance with the requirements of the company law, the Listing Rules of Shanghai Stock Exchange and other laws and regulations, as well as the articles of association and the rules of procedure of the general meeting of shareholders, fully considers the interests of shareholders, ensures that all shareholders, especially small and medium-sized shareholders, enjoy equal status and rights, and enables them to have the right to know and make decisions on major matters.
(III) directors and board of directors
The company has formulated the rules of procedure of the board of directors in accordance with the provisions of the company law and the articles of association, and elected directors in strict accordance with the specified selection and appointment procedures; The number and composition of the board of directors of the company meet the requirements of laws and regulations. The board of directors has an audit committee, a strategy committee, a remuneration and assessment committee and a nomination committee. The qualifications and election procedures of directors comply with the provisions of relevant laws and regulations. The independent directors of the company strictly abide by the working system of independent directors and the working system of annual report of independent directors, and can express independent opinions on major matters. All directors strictly abide by the statements and commitments made by the directors, earnestly perform the powers and obligations conferred by the articles of association, and perform their duties faithfully, diligently and in good faith.
(IV) supervisors and the board of supervisors
The company elects supervisors in strict accordance with the selection and employment procedures stipulated in the company law and the articles of association. The board of supervisors of the company is composed of three supervisors, one of whom is the employee representative. The number and personnel composition meet the requirements of laws and regulations. All supervisors can earnestly perform their duties in accordance with the rules of procedure of the board of supervisors and in the spirit of being responsible to all shareholders, especially small and medium-sized shareholders, Supervise the legality and compliance of the company’s finance and the performance of directors and senior managers, and fully safeguard the interests of the company and all shareholders.
(V) information disclosure
Guided by the needs of investors and based on compliance, the company strictly complies with the requirements of the standards for the contents and forms of information disclosure of companies offering securities to the public No. 2 – the contents and forms of annual reports (revised in 2021) issued by the China Securities Regulatory Commission and the guidelines for industrial information disclosure of listed companies No. 6 – pharmaceutical manufacturing issued by the Shanghai Stock Exchange, Actively fulfill the obligation of information disclosure, ensure the timeliness of information disclosure, and ensure that the disclosed information is true, accurate, complete, concise, clear and easy to understand.
The company appoints the Secretary of the board of directors to be responsible for information disclosure, and appoints China Securities News, Shanghai Securities News, securities daily and securities times as information disclosure newspapers. Strictly abide by the relevant provisions of information disclosure, effectively prevent the occurrence of selective information disclosure and insider trading, be fair, impartial and open, and ensure that all shareholders have equal access to information. In order to further standardize information disclosure, the company has also formulated information disclosure system and investor relations management system.
In order to standardize the company’s inside information management, strengthen the confidentiality of inside information and maintain the fairness of information disclosure, in accordance with the company law, the securities law, the measures for the administration of information disclosure of listed companies, the stock listing rules of Shanghai Stock Exchange and other laws and regulations and the relevant provisions of the company’s charter, and in combination with the actual situation of the company, The company has formulated the management system for inside information and insiders. The management of the company’s inside information is under the unified leadership and management of the board of directors to ensure that the files of insiders of the inside information are true, accurate and complete, and the chairman is the main responsible person. The Secretary of the board of directors organizes the implementation and is responsible for the registration and filing of the company’s insider information. The board of supervisors of the company supervises the implementation of the insider information management system.
The company strictly implements the insider information registration management system and strictly standardizes the information transmission process. During the period of regular report and temporary announcement disclosure, the Securities Affairs Department of the company will strictly control the scope of insiders of undisclosed information, organize to fill in the insider information registration form, and truthfully and completely record the list of insiders of the above information before disclosure, And the time when insiders know the inside information. The directors, supervisors, senior managers and other relevant personnel of the company strictly abide by the insider management system, and have not found any insider trading the company’s shares by using the insider information, and have not been subject to the supervision of the regulatory authorities due to the insider’s suspicion of insider trading
